Azah Syahrina Alias, Wai Kit Chia, Salwati Shuib, Wirda Indah Farouk, Chandramaya Sabrina Florence, Yin Ping Wong, Geok Chin Tan*
Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
*Geok Chin Tan, Department of Pathology, Faculty of Medicine, Hospital Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia; email@example.com
Breast cancer is the most common cancer affecting women in Malaysia. It is important to improve the prognosis of breast cancer for a better health care service. MicroRNAs are involved in various physiological and pathological processes, and miR-9 is already established as a potential prognostic biomarker for breast cancer. The aim of this study is to determine the expression of miR-9 in invasive breast carcinoma and its correlation with tumour grade, stage and receptor status. The expression of miR-9 was evaluated by in situ hybridisation in 47 cases of invasive breast carcinoma comprised of 33 cases of invasive carcinoma of no special type and 14 cases of invasive lobular carcinoma. MiR-9 was expressed in 20 of the 33 cases (60.6%) of invasive carcinoma of no special type. In contrast, only 1 (7.7%) of 14 cases of invasive lobular carcinoma expressed miR-9. However, there were no statistically significant differences between expressions of miR-9 and tumour grade, tumour size, lymph node metastasis and distant metastasis. The advantage of in situ hybridisation is the ability to localise the exact location of microRNA expression. MiR-9 was expressed in the majority of invasive carcinoma of no special type. In contrast, most invasive lobular carcinoma did not express miR-9.
Received: 18th November 2016
Accepted: 17th May 2017
Available online: 19th May 2017
Citing this article
Alias AS, Chia WK, Shuib S, et al. MicroRNA-9 expression study on invasive breast carcinoma using in situ hybridisation and its association with tumour characteristics. J Transdiscipl Biomed 2017; 1(1): X–X.
Copyright © 2017 by author(s) and EnPress Publisher LLC. This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).